PDL BioPharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
PDL BioPharma, Inc. had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $217.91 million as of 2020-08-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2021-03-29
- 2020-08-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $217.91M.
- 2019-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $266.20M.
- 2018-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $376.51M.
- 2017-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $349.22M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2020-08-31 | $217.91M 10-K · filed 2021-03-29 |
| 2019-12-31 | $266.20M 10-K · filed 2021-03-29 |
| 2018-12-31 | $376.51M 8-K · filed 2020-06-29 |
| 2017-12-31 | $349.22M 10-K · filed 2019-03-15 |
| 2016-12-31 | $402.32M 10-K · filed 2018-03-16 |
| 2015-12-31 | $399.20M 10-K · filed 2017-03-01 |
| 2015-09-30 | $384.57M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $280.73M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $269.67M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $259.24M 10-K · filed 2016-02-23 |
| 2014-09-30 | $242.45M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $247.12M 10-Q · filed 2014-08-18 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-23 |